NMRD) Announce Beta Launch of Proprietary MiBoKo Metabolic Health Program

Receive instant notifications when there is news about your stocks. Request your one-week free trial of StreetInsider Premium here.

  • Nemaura Medical is a medical technology company focused on developing non-invasive portable diagnostic devices
  • The company recently announced the beta launch of MiBoKo, a combo application and non-invasive glucose sensor designed to help users track their metabolic levels
  • In 2019 alone, diabetes-related health care spending in the US was $ 760 billion, equivalent to an annual spending of over $ 9,000 per diabetic

Nemaura Medical (NASDAQ: NMRD) is a cutting-edge medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company recently beta launched MiBoKo, a new proprietary metabolic health program that uses a non-invasive glucose sensor and an AI-based mobile application (

MiBoKo, an addition to Nemaura Medical’s diabetes-focused product portfolio, has been in development for the past 18 months and aims to address a significant and growing mass market opportunity that the company believes is about a third up to half of the &


NOTE TO INVESTORS: For the latest news and updates on NMRD, visit the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a biomedical news and content distribution company that provides (1) access to a network of wire services through InvestorWire to reach all target markets, industries and demographics in the most effective way, (2) article and editorials syndication (3) over 5,000 news outlets, expanded press releases to ensure maximum impact, (4) social media dissemination to nearly 2 million followers via the Investor Brand Network (IBN), (5) a full range of corporate communication solutions, and (6) a comprehensive solution for news reporting with BMW Prime. As a diverse company with an extensive team of contributing journalists and authors, BMW is uniquely positioned to best support private and public companies that seek to reach a wide audience of investors, consumers, journalists and the general public. By overcoming the flood of information in today’s market, BMW offers its customers unparalleled visibility, recognition and brand awareness. At BMW, news, content and information come together.

To receive SMS text alerts from BioMedWire, send an SMS with “STOCKS” to 77948 (US cell phones only)

More information is available at

Please note the full terms of use and disclaimers on the BioMedWire website, which apply to all content provided by BMW, regardless of where it is published or republished:

BioMedWire (BMW)
San Francisco, California
415.949.5050 office

BioMedWire is part of the InvestorBrandNetwork.

Related Articles